Evercore ISI analysts said the combo vaccine is a key product for Moderna, as it holds the potential ... antibody responses ...

The bivalent vaccine is designed to defend against BA.1, an Omicron subvariant, and an early strain of the novel coronavirus. Pfizer Inc. and Moderna Inc. have been developing their versions of ...

Northeastern University professors of pharmacy say the updated COVID-19 vaccines available for fall and winter of 2024 are a ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...

The Moderna laboratories Tuesday reported that their two bivalent Omicron-targeting new messenger RNA (mRNA) technology booster vaccines (mRNA-1273.214 and mRNA-1273.222) have a superior antibody ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

This time around, Moderna and Pfizer’s vaccines target the omicron variant known as KP.2 that was common earlier this year, and Novavax’s new vaccine targets KP.2’s parent strain, JN.1. Keep reading ...

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

The updated vaccine covers all major COVID variants that have developed so far, including previous Omicron strains and the new JN1 variant. Thanks to the flexibility of mRNA technology ...

Opinions expressed by Forbes Contributors are their own. Dave Wessner is a virologist who covers infectious diseases. In the continuing effort to mitigate the effects of Covid-19, the U.S. Food ...

A new variant of COVID called XEC — a combination of two Omicron subvariants — is spreading in the middle of flu season.